Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 655-663 , August 2008

Evaluation of a bromine-76-labeled progestin 16α,17α-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies

  • Dong Zhou

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Terry L. Sharp

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Nicole M. Fettig

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Hsiaoju Lee

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Jason S. Lewis

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • John A. Katzenellenbogen

      Affiliations

    • Department of Chemistry, University of Illinois, Urbana, IL 61801, USA
    • ,
  • Michael J. Welch

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • Corresponding Author InformationCorresponding author. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Tel.: +1 314 362 8436; fax: +1 314 362 8399.

Received 25 February 2008 ,Accepted 2 May 2008.

References 

  1. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–56
  2. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797–2803
  3. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose and 16α-[18F]fluoro-17α-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933–939
  4. Jonson SD, Bonasera TA, Dehdashti F, Cristel ME, Katzenellenbogen JA, Welch MJ. Comparative breast tumor imaging and comparative in vitro metabolism of 16β-[18F]fluoroestradiol-17β and 16β-[18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol. 1999;26:123–130
  5. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, et al. Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366–373
  6. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344–350
  7. McElvany KD, Welch MJ, Katzenellenbogen JA. Radiobrominated estrogen receptor-binding radiopharmaceuticals for breast tumor imaging. Nucl Med Biol Adv, Proc World Congr 3rd,. 1983;4:3610–3613
  8. Senderoff SG, McElvany KD, Carlson KE, Heiman DF, Katzenellenbogen JA, Welch MJ. Methodology for the synthesis and specific activity determination of 16β-[77Br]-bromoestradiol-17α and 16α-[77Br]-bromo-11β-methoxyestradiol-17β, two estrogen receptor-binding radiopharmaceuticals. Int J Appl Radiat Isot. 1982;33:545–551
  9. Katzenellenbogen JA, McElvany KD, Senderoff SG, Carlson KE, Landvatter SW, Welch MJ. 16α-[77Br]Bromo-11β-methoxyestradiol-17β: a gamma-emitting estrogen imaging agent with high uptake and retention by target organs. J Nucl Med. 1982;23:411–419
  10. Katzenellenbogen JA, Senderoff SG, McElvany KD, O'Brien HA, Welch MJ. 16α-[Bromine-77]bromoestradiol-17β: a high specific-activity, gamma-emitting tracer with uptake in rat uterus and induced mammary tumors. J Nucl Med. 1981;22:42–47
  11. Landvatter SW, Katzenellenbogen JA, McElvany KD, Welch MJ. (2R⁎,3S⁎)-1-[125I]Iodo-2,3-bis(4-hydroxyphenyl)pentane ([125I]iodonorhexestrol) and (2R⁎,3S⁎)-1-[77Br]bromo-2,3-bis(4-hydroxyphenyl)pentane ([77Br]bromonorhexestrol), two gamma-emitting estrogens that show receptor-mediated uptake by target tissues in vivo. J Med Chem. 1982;25:1307–1312
  12. McElvany KD, Katzenellenbogen JA, Shafer KE, Siegel BA, Senderoff SG, Welch MJ. 16 alpha-[77Br]Bromoestradiol: dosimetry and preliminary clinical studies. J Nucl Med. 1982;23:425–430
  13. Bronzert DA, Hochberg RB, Lippman ME. Specific cytotoxicity of 16 alpha-[125I]iodoestradiol for estrogen receptor-containing breast cancer cells. Endocrinology. 1982;110:2177–2182
  14. Bloomer WD, McLaughlin WH, Milius RA, Weichselbaum RR, Adelstein SJ. Estrogen receptor-mediated cytotoxicity using iodine-125. J Cell Biochem. 1983;21:39–45
  15. McLaughlin WH, Pillai KM, Edasery JP, Blumenthal RD, Bloomer WD. [125I]Iodotamoxifen cytotoxicity in cultured human (MCF-7) breast cancer cells. J Steroid Biochem. 1989;33:515–519
  16. McLaughlin WH, Milius RA, Pillai KMR, Edasery JP, Blumenthal RD, Bloomer WD. Cytotoxicity of receptor-mediated 16α-[125I]iodoestradiol in cultured MCF-7 human breast cancer cells. J Natl Cancer Inst. 1989;81:437–440
  17. Epperly MW, Damodaran KM, McLaughlin WH, Pillai KM, Bloomer WD. Radiotoxicity of 17-alpha-[125I]iodovinyl-11-beta-methoxyestradiol in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol. 1991;39:729–734
  18. Beckmann MW, Scharl A, Rosinsky BJ, Holt JA. Breaks in DNA accompany estrogen-receptor-mediated cytotoxicity from 16-alpha[125I]iodo-17 beta-estradiol. J Cancer Res Clin Oncol. 1993;119:207–214
  19. DeSombre ER, Mease RC, Hughes A, Harper PV, DeJesus OT, Friedman AM. Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. Cancer Res. 1988;48:899–906
  20. DeSombre ER, Shafii B, Hanson RN, Kuivanen PC, Hughes A. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res. 1992;52:5752–5758
  21. Schwartz JL, Mustafi R, Hughes A, DeSombre ER. DNA and chromosome breaks induced by iodine-123-labeled estrogen in Chinese hamster ovary cells. Radiat Res. 1996;46:151–158
  22. DeSombre ER, Hughes A, Landel CC, Greene G, Hanson R, Schwartz JL. Cellular and subcellular studies of the radiation effects of Auger electron-emitting estrogens. Acta Oncologica. 1996;35:833–840
  23. Kassis AI, Adelstein SJ, Haydock C, Sastry KSR, McElvany KD, Welch MJ. Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res. 1982;90:362–373
  24. Tang L. Radionuclide Production and Yields at Washington University School of Medicine. Q J Nucl Med Mol Imag. 2008;52:121–133
  25. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–7735
  26. Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005;14:458–465
  27. Horowitz KB. The structure and function of progesterone receptors in breast cancer. J Steroid Biochem. 1987;27:447–457
  28. Santen R, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocrine Rev. 1990;11:221–265
  29. Gelbfish GA, Davison AL, Kopel S, Schreibmen B, Gelbfish JS, Degenshein GA, et al. Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann Surg. 1988;207:75–79
  30. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25:127–205
  31. Noguchi S, Miyauchi K, Nishizawa Y, Koyama H. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time. Cancer. 1988;61:1345–1349
  32. Howell A, Harland RNL, Barnes DM, Baildam AD, Wilkinson MJS, Hayward E, et al. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res. 1987;47:300–304
  33. Namer M, Lalanne C, Baulieu E. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res. 1980;40:1750–1752
  34. Zhou D, Carlson KE, Katzenellenbogen JA, Welch MJ. Bromine- and iodine-substituted 16α,17α-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J Med Chem. 2006;49:4737–4744
  35. Buckman BO, Bonasera TA, Kirschbaum KS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled progestin 16α,17α-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J Med Chem. 1995;38:328–337
  36. Kochanny MJ, VanBrocklin HF, Kym PR, Carlson KE, O'Neil JP, Bonasera TA, et al. Fluorine-18 labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. J Med Chem. 1993;36:1120–1127
  37. Denat F, Gaspard-Iloughmane H, Dubac J. An easy one-pot synthesis of Group 14 C-metallated 2(or 3)-furan- and thiophenecarboxaldehydes. Synthesis. 1992;10:954–956
  38. Vijaykumar D, Wang M, Kirschbaum KS, Katzenellenbogen JA. An efficient route for the preparation of a 21-fluoro progestin-16α,17α-dioxolane, a high-affinity ligand for PET imaging of the progesterone receptor. J Org Chem. 2002;67:4904–4910
  39. Van Den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol. 2004;22:3593–3607
  40. Katzenellenbogen JA, Heiman DF, Carlson KE, Lloyd JE. In vivo and in vitro steroid receptor assays in the design of estrogen radiopharmaceuticals. In:  Eckelman WC editors. Receptor-Binding Radiotracers. Vol. 1:Boca Raton (Fla): CRC; 1982;p. 93–126
  41. Dehdashti F, McGuire AH, Van Brocklin HF, Siegel BA, Andriole DP, Griffeth LK, et al. Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med. 1991;32:1532–1537
  42. Verhagen A, Studeny M, Luurtsema G, Visser GM, De Goeij CC, Sluyser M, et al. Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol. 1994;7:941–952
  43. Pomper MG, VanBrocklin H, Thieme AM, Thomas RD, Kiesewetter DO, Carlson KE, et al. 11β-Methoxy-, 11β-ethyl- and 17α-ethynyl-substituted 16α-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. J Med Chem. 1990;33:3143–3155
  44. VanBrocklin HF, Pomper MG, Carlson KE, Welch MJ, Katzevellenbogen JA. Preparation and evaluation of 17-ethynyl-substituted 16α-[18F]fluoroestradiols: selective receptor-based PET imaging agents. Nucl Med Biol. 1992;19:363–374
  45. VanBrocklin HF, Rocque PA, Lee HV, Carlson KE, Katzenellenbogen JA. 16β-[18F]Fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors. Life Sciences. 1993;53:811–819
  46. Hanson RN. The influence of structure modification on the metabolic transformations of radiolabeled estrogen derivatives. In:  Nunn A editors. Radiopharmaceutical: chemistry and pharmacology. New York: Marcel Dekker; 1992;p. 333–364
  47. Soremark R, Ullberg S. Distribution of bromide in mice. An autoradiographic study with Br-82. Int J Appl Radiat Isot. 1960;8:192–197
  48. Lee H, Finck BN, Jones LA, Welch MJ, Mach RH. Synthesis and evaluation of a bromine-76-labeled PPARγ antagonist 2-bromo-5-nitro-N-phenylbenzamide. Nucl Med Biol. 2006;33:847–854
  49. Müller K, Faeh C, Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science. 2007;317:1881–1886
  50. Mathias CJ, Welch MJ, Katzenellenbogen JA, Brodack JW, Kilbourn MR, Carlson KE, et al. Characterization of the uptake of 16α-([18F]fluoro)-17β-estradiol in DMBA-induced mammary tumors. Int J Rad Appl Instrum B. 1987;14:15–25

☆ This work was supported by the DOE (DE FG02 86ER60401 to JAK and DE FG02-84ER-60218 to MJW) and the NIH (PHS 2R01 CA25836 to JAK).

PII: S0969-8051(08)00108-X

doi: 10.1016/j.nucmedbio.2008.05.001

Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 655-663 , August 2008

Article Tools

* Image Usage & Resolution